Baxter Expands Cancer Therapies With $900M Oncaspar Buy
American health care company Baxter International Inc. will pay Italian company Sigma-Tau Finanziaria S.p.A. $900 million for blockbuster leukemia treatment Oncaspar and at least one other cancer drug still in development,...To view the full article, register now.
Already a subscriber? Click here to view full article